- Home
- BIAF vs NCNA Comparison
BIAF vs NCNA Comparison
Compare BIAF & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIAF | NCNA |
|---|---|---|
| Founded | 2014 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 7.6M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BIAF | NCNA |
|---|---|---|
| Price | $1.63 | $4.16 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 99.0K | 65.6K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,776,739.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $20.04 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.25 | $2.78 |
| 52 Week High | $46.53 | $330.00 |
Technical Indicators
Market Signals| Indicator | BIAF | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 53.56 |
| Support Level | $1.34 | $3.82 |
| Resistance Level | $1.79 | $4.54 |
| Average True Range (ATR) | 0.14 | 0.28 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 74.09 | 72.18 |
Price Performance
Historical ComparisonAbout BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.